Pricing Log in Create free account
Friday 6 November 2026 Export IBRX’s income statement to Excel — free account

ImmunityBio, Inc.

IBRX Healthcare Biotechnology

ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024.

Revenue
+93.9%
EPS
−120.0%
Free cash flow
+13.4%
Total debt
+57.4%

Quarter to June 2026, against a year earlier

8.51 0.50 +6.24%
Market cap
$8.5B
P/E
0.0×
Fwd P/E
−8.7×
Dividend yield
—
F-score
4/9
Altman Z
−10.16
Beneish M
4.57
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

ImmunityBio, Inc. (IBRX) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
8-K Oct 14, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 32 added · 27 removed · 42 modified
P2I1A: no comparison — low extraction confidence 		Share dilution Receivables outpacing revenue
8-K Aug 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jul 29, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Jun 9, 2026 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits
8-K May 14, 2026 1.01 Entry into a material definitive agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K May 7, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 9, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 6, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Mar 30, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 260 added · 132 removed · 96 modified
1A: 24 added · 8 removed · 162 modified
7: 64 added · 53 removed · 39 modified 		Auditor change
8-K Feb 23, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 18, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jan 23, 2026 1.01 Entry into a material definitive agreement; 9.01 Financial statements and exhibits
8-K Jan 15, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 14, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Dec 23, 2025 1.01 Entry into a material definitive agreement; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Dec 10, 2025 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits Officer departure
8-K Dec 12, 2025 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Nov 4, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Aug 5, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jul 24, 2025 1.01 Entry into a material definitive agreement; 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K May 12, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 15, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Mar 3, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Nov 12, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.